Join the Abrysvo group to help and get support from people like you.
Abrysvo News (Page 2)
Optimal Timing of Maternal RSV Vaccine Determined to Be at Least Five Weeks Before Delivery
THURSDAY, Nov. 21, 2024 – Respiratory syncytial virus (RSV) vaccination at least five weeks prior to delivery results in the highest transplacental transfer of maternal antibodies to the neonate,...
RSV Hospitalizations Linked to Considerable Burden in Adults
FRIDAY, Nov. 15, 2024 – Respiratory syncytial virus (RSV) is associated with a considerable burden of hospitalizations, intensive care unit (ICU) admissions, and in-hospital deaths among adults,...
RSV Vaccination Prevents Associated Hospitalization, Emergency Encounters
THURSDAY, Nov. 7, 2024 – For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated hospitalizations and emergency department encounters,...
Monthly News Roundup - October 2024
FDA Approves AbbVie’s Vyalev to Treat Advanced Parkinson Disease In October, the US Food and Drug Administration (FDA) approved Vyalev (foscarbidopa and foslevodopa) for the treatment of motor f...
U.S. FDA Approves Pfizer’s RSV Vaccine Abrysvo for Adults Aged 18 to 59 at Increased Risk for Disease
NEW YORK--(BUSINESS WIRE) October 22, 2024 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the...
Real-World Study Confirms RSV Vaccine's, Arexvy and Abrysvo, Protective Power for Seniors
FRIDAY, Oct. 18, 2024 – A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or...
IDSA: Vaccination Less Likely With Increasing Social Vulnerability, Black Race
FRIDAY, Oct. 18, 2024 – Vaccination for influenza, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and respiratory syncytial virus (RSV) is less likely with an increasing social...
Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat
WEDNESDAY, Oct. 16, 2024 – Public concerns about contracting RSV (respiratory syncytial virus) have significantly declined during the past year, a new survey shows. About 1 in 4 people (26%) are now...
More Than Half of Infants Protected by Maternal RSV Vaccine, Nirsevimab, or Both
FRIDAY, Sept. 27, 2024 – In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according to research...
U.S. FDA Approves Abrysvo, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
NEW YORK--(BUSINESS WIRE) August 21, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo™ (Respiratory Syncytial Virus Vaccine), the c...
FDA Approves Abrysvo (respiratory syncytial virus vaccine) for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
NEW YORK--(BUSINESS WIRE) May 31, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo™ (Respiratory Syncytial Virus Vaccine), the c...